Vikas Veer: Exploring Sickle Cell Anemia at the Molecular Level
Vikas Veer, Chief Executive Officer at dumblearner.com, shared a post on LinkedIn:
“Sickle Cell Anemia at the molecular level: a single amino acid substitution (glutamic acid – valine) alters hemoglobin’s polymerization behavior, causing red blood cells to deform into a rigid sickle shape once deoxygenated.
The downstream clinical picture is well known to most clinicians – vaso-occlusive pain episodes, acute chest syndrome, stroke risk in pediatric patients, and early splenic autoinfarction – but the underlying biomechanics are worth revisiting, especially for patient education purposes.
This short breaks down the pathophysiology, inheritance pattern (autosomal recessive, nearly 25% risk with two carrier parents), U.S. prevalence (nearly 1 in 400 African American newborns), and current management options including hydroxyurea and bone marrow transplant.
Useful for anyone building patient-facing education content or explaining genetic blood disorders to non-clinical audiences.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 06:48Gopal Patidar: Honoured to Contribute to the ASFA 2026 Guidelines for Therapeutic Apheresis
-
Sep 18, 2026, 05:48Julie Taylor: Navigating Tech Glitches to Deliver Engaging BBTS Presentation
-
Sep 18, 2026, 05:42Emma Copperwaite: BBTS Conference Presentation Highlights Power of Peer Support and Pushing Past Fear
-
Sep 18, 2026, 05:34Suhasini Sil: RGSSH Joins Mega Blood Donation Camp at Thyagaraj Stadium
-
Sep 18, 2026, 05:25Lisa Laun: Spleen Clears Activated Platelets to Limit Thrombosis and Inflammation
-
Sep 18, 2026, 05:16Louise St. Germain Bannon: ISTH Advocates for Enhanced Patient Safety in Blood Disorder Care
-
Sep 18, 2026, 01:35Matthew Hazell: From Platelet Refractoriness to Protecting Transplanted Organs
-
Sep 18, 2026, 01:23Apple Joy A. Valenzuela: Exploring How Neutrophil Develops from the Myeloblast to the Mature Segmented Neutrophil
-
Sep 18, 2026, 01:13Su Someh: Gaps and Variation in Global Plasma Donor Protection Policies